Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,953,600 | 4,338,400 | 8,075,300 | 3,513,200 | 2,115,800 |
| Depreciation Amortization | 421,000 | 341,400 | 286,200 | 235,900 | 210,300 |
| Income taxes - deferred | -837,800 | -746,400 | -147,100 | 75,600 | -130,600 |
| Accounts receivable | -338,800 | 707,800 | -1,927,400 | -1,356,100 | -523,700 |
| Other Working Capital | -94,100 | -243,300 | -1,916,500 | -1,503,600 | -200,500 |
| Other Operating Activity | 1,490,100 | 617,000 | 2,710,800 | 1,653,100 | 958,700 |
| Operating Cash Flow | $4,594,000 | $5,014,900 | $7,081,300 | $2,618,100 | $2,430,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -2,203,800 | -1,937,400 | -4,832,800 | 544,000 | -1,598,200 |
| PPE Investments | -718,600 | -590,100 | -551,900 | -614,600 | -429,600 |
| Net Acquisitions | -54,900 | -230,300 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -207,800 | -1,026,800 | 0 | N/A | N/A |
| Other Investing Activity | -207,800 | -1,026,800 | 0 | 0 | 0 |
| Investing Cash Flow | $-3,185,100 | $-3,784,600 | $-5,384,700 | $-70,600 | $-2,027,800 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 1,500,000 | 0 |
| Debt Issued | N/A | N/A | N/A | 1,981,900 | 0 |
| Common Stock Issued | 1,145,500 | 1,519,500 | 1,672,300 | 2,575,200 | 211,800 |
| Common Stock Repurchased | -2,935,600 | -2,528,500 | -2,678,100 | -6,527,600 | -463,900 |
| Other Financing Activity | 0 | 0 | 0 | -1,500,000 | 0 |
| Financing Cash Flow | $-1,790,100 | $-1,009,000 | $-1,005,800 | $-1,970,500 | $-252,100 |
| Exchange Rate Effect | -400 | 0 | 0 | N/A | N/A |
| Beginning Cash Position | 3,119,400 | 2,898,100 | 2,207,300 | 1,630,300 | 1,480,200 |
| End Cash Position | 2,737,800 | 3,119,400 | 2,898,100 | 2,207,300 | 1,630,300 |
| Net Cash Flow | $-381,600 | $221,300 | $690,800 | $577,000 | $150,100 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,594,000 | 5,014,900 | 7,081,300 | 2,618,100 | 2,430,000 |
| Capital Expenditure | -718,600 | -590,100 | -551,900 | -614,600 | -429,600 |
| Free Cash Flow | 3,875,400 | 4,424,800 | 6,529,400 | 2,003,500 | 2,000,400 |